Yiqun Han

Yiqun Han

Mayo Clinic - Rochester / United States
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 5148790
Mayo Clinic College of Medicine and Science
person_outline Yiqun Han's MOST POPULAR ARTICLES
1-) RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies.J Wang, Y Liu, Q Zhang, J Feng, J Fang, X Chen, Y Han, Q Li, P Zhang, ...Journal of Clinical Oncology 39 (15_suppl), 1022-1022, 2021732021
2-) Clinicopathological characteristics and prognosis of breast cancer with special histological types: a surveillance, epidemiology, and end results database analysisY Han, J Wang, B XuThe Breast 54, 114-120, 2020402020
3-) Clinicopathological characteristics and prognosis of HER2-low early-stage breast cancer: a single-institution experienceH Xu, Y Han, Y Wu, Y Wang, Q Li, P Zhang, P Yuan, Y Luo, Y Fan, S Chen, ...Frontiers in oncology 12, 906011, 2022352022
4-) Abstract PD4-06: Early clinical development of RC48-ADC in patients with HER2 positive metastatic breast cancerB Xu, J Wang, J Fang, X Chen, Y Han, Q Li, P Zhang, P Yuan, F Ma, Y Luo, ...Cancer Research 80 (4_Supplement), PD4-06-PD4-06, 2020312020
5-) Profile and outcome of receptor conversion in breast cancer metastases: a nation‐wide multicenter epidemiological studyZB Yi, P Yu, S Zhang, WN Wang, YQ Han, QC Ouyang, M Yan, XJ Wang, ...International Journal of Cancer 148 (3), 692-701, 2021192021